TCTN3

Across TCGA pan-cancer cohorts, TCTN3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TCTN3 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TCTN3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TCTN3 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where TCTN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.275	0.841	.001	27	view →
LUAD	DFS	Tertile	II,III,IV	0.342	0.761	.006	16	view →
GBM	DFS	Median	All	0.411	0.285	.027	5	view →
CCRCC	OS	Median	All	0.864	1.000	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TCTN3–PDAC (OS)

Open the PDAC breakdown →